Introduction
============

It is well known that hepatocellular carcinoma (HCC) is highly prevalent worldwide, especially in B- and C-type hepatitis virus endemic areas [@B1]. In addition, the overall prognosis of HCC remains poor, although some improved results have been achieved by curative interventions, such as hepatic resection and liver transplantation in highly selected patients [@B2],[@B3]. Therefore, factors affecting prognosis of HCC were long of interest. Except for conventional clinical and pathologic variables that were previously reported and summarized, such as portal vein thrombosis, tumor size, alpha-fetoprotein (AFP), Child-Pugh class and tumor-node-metastasis (TNM) stage [@B4]-[@B6], prognostic values of molecules that are involved in initiation and progression of HCC, including genes/proteins, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) have been gradually found [@B7]-[@B9]. However, novel promising candidates need to be further explored.

G protein-coupled receptor kinase 3 (GRK3) is one of seven isoforms of GRKs that phosphorylate and desensitize agonist-bound G protein-coupled receptors (GPCRs) [@B10],[@B11]. It was previously demonstrated that GRK3 plays important roles in the nerve system [@B12]-[@B14]. Interestingly, data concerning GRK3 seem to be controversial in different kinds of human malignant tumors [@B15]-[@B18]. In glioblastoma, GRK3 was found to be frequently decreased and to reduce the trophic effect of endothelial cells on tumor cells [@B15]. Recent results from breast cancer also suggested its negative impact on migration, invasion, and metastasis [@B16]. However, Li et al. reported that GRK3 not only maintained survival and proliferation of metastatic cells, but also promoted growth, neuroendocrine differentiation and metastasis in prostate cancer [@B17],[@B18]. Therefore, the biological effects of GRK3 might be tissue-type specific. This phenomenon might influence the impact of the molecule on clinical features and long-term outcomes in patients with different malignancies. Thus far, expression, clinicopathologic and prognostic significances of GRK3 in cancer remain unknown.

The present study was designed to address these issues, based on Chinese patients with HCC.

Materials and Methods
=====================

Patients and Samples
--------------------

Totally, 8 and 395 patients with HCC who underwent hepatectomy were enrolled, respectively. Paired tumor and adjacent non-tumor liver tissues were obtained. Of 8 patients whose samples were collected for Western blotting, 6 were male and 2 were female. Ages ranged from 16 to 60 years (median: 53 years). On the other hand, 395 individuals whose samples for immunohistochemistry were divided into two independent sets, i.e. training (2010-2012, n=164) and validation (2005-2009, n=231) ones. Among the patients, 334 (84.6%) were male and 61 (15.4%) were female, with the median age of 52 years (range: 17-79 years). The tested clinicopathologic parameters were age, sex, hepatitis B surface antigen (HBsAg), cirrhosis, tumor size, vascular invasion, Edmondson-Steiner grade [@B19], TNM stage and AFP level. Tumor size was first measured in preoperative imaging and proven during operation. Vascular invasion (VI) and Edmondson-Steiner grade were determined by post-surgical histological examinations. Patient clinicopathologic features are shown in Table [1](#T1){ref-type="table"}. The project was approved by the Institutional Ethics Committee and the informed consent of patients was obtained.

Western Blotting
----------------

Proteins were extracted according to tissue protein extraction protocols. Protein extracts (60μg/lane) were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by transfer to polyvinylidene difluoride (PVDF) membranes and blocking with 5% bovine serum albumin (BSA) for 2h. A rabbit anti-human monoclonal antibody against GRK3 (Abcam, Cambridge, UK) were incubated overnight at 4°C. Then, a horseradish peroxidase-conjugated secondary antibody was incubated for 2h at room temperature. Blots were washed three times and exposed to chemiluminescence reagents (Merck Millipore, Darmstadt, Germany). GAPDH was used as the internal control.

Tissue Microarray (TMA) Construction
------------------------------------

TMAs were constructed based on formalin-fixed paraffin-embedded blocks of HCC. Firstly, representtative areas within tumor and adjacent non-tumor liver tissues were re-identified. Then, cores with a diameter of 1.5 mm were sampled. Finally, TMAs were constructed using a manual tissue arrayer (Beecher Instruments, Sun Prairie, WI).

Immunohistochemical Staining
----------------------------

The same primary antibody for GRK3 was used for staining. In the first, 4 µm-thick sections were mounted, deparaffinized in xylene and rehydrated in graded ethanol. Antigen retrieval was carried out in an autoclave for 5 min. Subsequently, slides were incubated with hydrogen peroxide (3%) for 10 min to block endogenous peroxidase. Slides were then incubated overnight with the primary antibody (1: 100) at 4ºC. Non-immune serum at the same dilution was applied as the negative control. After washing in phosphate buffered saline (PBS), the horseradish peroxidase (HRP)-labeled secondary antibody was added for an incubation of 30 min. Diaminobenzidine was adopted as a chromogen. Finally, slides were counterstained using hematoxylin.

Staining Evaluation
-------------------

Two senior pathologists who had no prior information of clinicopathologic and follow-up data (Z.Y. L. and W.X. Z.) independently evaluated the slides, and discussed for the consensus when they were divergent. The positive signal was defined as brown coloration in tumor and non-tumor liver cells. The H-score [@B20], considering both positive cell proportion and staining intensity and being widely adopted in immunostaining studies [@B21],[@B22], was used as the staining evaluation criteria. The H-score values with the largest youden index (YI) for survival and clinicopathologic variables within corresponding receiver operating characteristic (ROC) curves were selected as cut-off ones, as previously reported [@B23].

Follow-Up
---------

All patients underwent follow-up. For the training set, median follow-up time was 20.0 months (range, 1.4 to 44.0 months). For the validation set, the follow-up time ranged from 1.3 to 115.8 months (median, 28.9 months).

Statistical Analyses
--------------------

H-scores of GRK3 staining in tumor and adjacent non-tumor liver tissues were compared by Mann-Whitney *U* test. The associations between GRK3 expression and clinicopathologic variables were determined using Chi-square analysis. Patient tumor-specific survival was analyzed by Kaplan-Meier method and log-rank test. Multivariate prognostic factor analyses were performed using Cox regression (Proportional hazard model). The statistical software package, SPSS11.5 (SPSS Inc, Chicago, IL), was applied for all the analyses. A *P* value less than 0.05 was defined as statistically significant.

Results
=======

Expression of GRK3 in Patients of HCC (Detected by Western Blotting)
--------------------------------------------------------------------

Western blotting showed that GRK3 was degressively expressed in 4 out of 8 tumor tissues (patients 3, 4, 5 and 6), in contrast to corresponding non-tumor ones (Fig. [1](#F1){ref-type="fig"}). Besides, its expression in tumors was higher than and equal to that in normal tissues in 2 (1 and 7) and 2 (2 and 8) patients, respecttively. The corresponding hematoxylin and eosin (H&E) staining images of tumor and non-tumor tissues of these patients were shown to provide histological evidence in Fig. [S1](#SM1){ref-type="supplementary-material"}.

Cut-off Values of GRK3 for Survival and Clinicopathologic Variables of HCC
--------------------------------------------------------------------------

According to ROC curves for main clinicopathologic variables of the training set (Fig. [S2](#SM1){ref-type="supplementary-material"}), cut-off values of GRK3 H-score for survival, AFP level, Edmondson-Steiner grade, vascular invasion, tumor size and TNM stage were 51.25, 160, 68.75, 109.375, 61.875 and 51.25, respectively.

GRK3 Expression and Associations with Clinicopathologic Features in HCC
-----------------------------------------------------------------------

It was revealed that the positive signal of GRK3 was basically located in the cytoplasm of both tumor and adjacent non-tumor liver tissues (Fig. [2](#F2){ref-type="fig"}A, B, D and E). The H-scores of GRK3 in tumors were much lower than those in adjacent non-tumor liver tissues in both training and validation sets (All *P*\<0.001; Fig. [2](#F2){ref-type="fig"}C and F).

As shown in Table [1](#T1){ref-type="table"}, GRK3 expression was negatively associated with tumor size (*P*=0.018), VI (*P*=0.022), TNM stage (*P*=0.023) and serum AFP level (*P*\<0.001) in the training set. On the other hand, this protein was related to Edmondson-Steiner grade (*P*\<0.001), TNM stage (*P*\<0.001) and serum AFP level (*P*=0.035) in the validation set (Table [1](#T1){ref-type="table"}). Other statistically significant correlations were not found.

Prognostic Significance of GRK3 in HCC
--------------------------------------

Univariate analysis showed that patients with high GRK3 expressed HCCs carried more favorable tumor-specific survival, in comparison to those with low GRK3 tumors, in both training and validation sets of HCC (*P*=0.041 and 0.002, respectively; Fig. [3](#F3){ref-type="fig"}, Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Using multivariate Cox regression test, GRK3 expression was identified as an independent predictor of good prognosis in training and validation sets of HCC (*P*=0.006 and 0.012, respectively; Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}), adjusted for tested conventional clinicopathologic parameters, including age, sex, HBsAg, cirrhosis, tumor size, vascular invasion, Edmondson-Steiner grade, TNM stage and AFP level.

Furthermore, GRK3 expression was also found to be prognostic in all patients and 7 out of 10 subgroups of HCC, i.e. tumor size ≥5cm, with vascular invasion, Edmondson-Steiner grade I-II, Edmondson-Steiner grade III-IV, TNM stage III-IV~A~, AFP level ≤20ng/ml and AFP level \>20ng/ml, in univariate analysis (All *P*\<0.05; Fig. [4](#F4){ref-type="fig"}). Multivariate Cox regression test revealed that GRK3 expression was of independent impacts on prognosis in all patients and 5 subgroups (tumor size ≥5cm, with vascular invasion, Edmondson-Steiner grade III-IV, TNM stage III-IV~A~ and AFP level \>20ng/ml) of HCC (All *P*\<0.05; Table [4](#T4){ref-type="table"}), together with some clinicopathologic variables.

Discussion
==========

GRK3, an isoform of GRKs that has direct catalytic effects for phosphorylation and desensitization of GPCRs [@B10],[@B11], was proven to play pivotal roles in tissues, such as the nerve system [@B12]-[@B14]. Thus far, reports about GRK3 in human malignancies remains to be limited, but inconsistent, even opposite [@B15]-[@B18]. It was shown that GRK3 was negatively associated with aggressive behaviors in glioblastoma and breast cancer [@B15],[@B16], whereas this gene was also established to be involved in survival and proliferation of metastatic cells, as well as tumor growth, neuroendocrine differentiation and metastasis, in prostate cancer [@B17],[@B18]. Therefore, GRK3 might be a protein that functions tissue-type specifically. Besides, expression and clinicopathologic significances of GRK3 in cancer have not been explored. The present study was designed to address the issues. In the first, authors found by Western blotting that GRK3 expression was low in tumor tissues, in contrast to adjacent non-tumor liver tissues, in half (4 out of 8) pairs of samples (Fig. [1](#F1){ref-type="fig"}), preliminarily indicating its frequent down-regulated expression in HCC. The subsequent finding based on HCC patients in a relatively recent time period as the training set is that H-score of GRK3 staining was much lower in tumor tissues than in non-tumor tissues (Fig. [2](#F2){ref-type="fig"}A-C). In addition, H-scores of GRK3 staining were negatively correlated with tumor size, VI, TNM stage and serum AFP level (Table [1](#T1){ref-type="table"}), variables that were linked to progression of HCC [@B24]-[@B27], under cut-off values derived from ROC curves (Fig. [S2](#SM1){ref-type="supplementary-material"}). Besides, these observations were strongly supported by similar ones in the validation set. In particular, the negative relationship between GRK3 expression and TNM stage as well as serum AFP level was found in both sets. No doubt TNM stage largely reflects tumor progression, while AFP were long demonstrated to contribute to malignant phenotypes, for example, growth, host immune inhibition and metastasis, through multiple mechanisms in hepatocarcinogenesis [@B28]-[@B30]. Therefore, GRK3 seems to be a negative marker of HCC progression. Moreover, whether AFP is involved in GRK3-induced alterations in phenotypes and corresponding molecules of HCC might also be of interest. In the future, relative mechanistic investigations on GRK3 are quite expected.

On the other hand, the prognostic value of GRK3 in cancer remains unknown. In this work, the authors first showed in the training set that patients with high GRK3 expression had significantly good survival in univariate analysis (Fig. [3](#F3){ref-type="fig"}A, Table [2](#T2){ref-type="table"}), while GRK3 remained to be significantly prognostic in multivariate Cox regression analysis (Table [2](#T2){ref-type="table"}), adjusted for conventional clinicopathologic variables. Similar with results for clinicopathologic significance, its prognostic implication was also confirmed in the validation set (Fig. [3](#F3){ref-type="fig"}B, Table [3](#T3){ref-type="table"}). Moreover, GRK3 expression was also revealed to distinguish good and poor survival in all patients and 7 out of 10 subsets of HCC in univariate analysis (Fig. [4](#F4){ref-type="fig"}), and independently predicted prognosis in all patients and 5 subsets based on multivariate Cox regression test (Table [4](#T4){ref-type="table"}). All these data suggest that GRK3 might have a broad potential to serve as a promising biomarker for favorable prognosis in many groups of HCC. In view of the negative correlation between GRK3 expression and aggressive parameters, especially late TNM stage and high AFP level, the survival benefit of GRK3-high HCC might be easily understood. Thus, we here add a novel candidate of molecular markers in outcome prediction of HCC [@B7]-[@B9].

Collectively, our data establish that GRK3 is down-regulated and is predictive for favorable prognosis in HCC. Therefore, this gene might function as a tumor suppressor gene (TSG) in HCC.
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![Expression of G protein-coupled receptor kinase 3 (GRK3) in hepatocellular carcinoma (HCC), detected by Western blotting. T, tumor; N, non-tumor; GRK3, G protein-coupled receptor kinase 3.](jcav08p1972g001){#F1}

![Expression of G protein-coupled receptor kinase 3 (GRK3) in two sets of hepatocellular carcinoma (HCC). (**A**) GRK3 expression in tumor tissues of training set (×200); (**B**) GRK3 expression in adjacent non-tumor liver tissues of training set (×200); (**C**) The H-score in tumor tissues was statistically lower than that in adjacent non-tumor liver ones of training set; (**D**) GRK3 expression in tumor tissues of validation set (×200); (**E**) GRK3 expression in adjacent non-tumor liver tissues of validation set (×200); (**F**) The H-score in tumor tissues was statistically lower than that in adjacent non-tumor liver ones of validation set.](jcav08p1972g002){#F2}

![Prognostic impacts of G protein-coupled receptor kinase 3 (GRK3) in two sets of hepatocellular carcinoma (HCC). (**A**) Training set; (**B**) Validation set.](jcav08p1972g003){#F3}

![Significant prognostic impacts of G protein-coupled receptor kinase 3 (GRK3) in all patients and seven subgroups of hepatocellular carcinoma (HCC). (**A**) All patients; (**B**) alpha-fetoprotein (AFP) level ≤20ng/ml; (**C**) AFP level \>20ng/ml; (**D**) Edmondson-Steiner (E-S) grade I-II; (**E**) E-S grade III-IV; (**F**) With vascular invasion; (**G**) Tumor size ≥5 cm; (**H**) tumor-node-metastasis (TNM) stage III-IV~A~.](jcav08p1972g004){#F4}

###### 

Associations between GRK3 expression and clinicopathologic features in HCC

  Variables                  GRK3 in training set        GRK3 in validation set                          
  ------------ ------------- ---------------------- ---- ------------------------ -- ----- ------- ----- --
  Age          0.115                                     0.204                                           
  ≥52 years    88            42                     46                               116   15      101   
  \<52 years   76            27                     49                               115   9       106   
  Sex          0.170                                     0.089                                           
  Male         137           124                    13                               197   42      155   
  Female       27            22                     5                                34    3       31    
  HBsAg                                                  0.542                             0.089         
  Positive     141           101                    40                               174   40      134   
  Negative     20            13                     7                                44    5       39    
  Cirrhosis    0.243                                     0.155                                           
  Present      145           105                    40                               191   3       188   
  Absent       17            10                     7                                38    2       36    
  Tumor size                                             **0.018**                         0.090         
  ≥5 cm        97            47                     50                               138   95      43    
  \<5cm        67            45                     22                               74    59      15    
  VI                                                     **0.022**                         0.118         
  Present      76            15                     61                               116   37      79    
  Absent       80            29                     51                               92    39      53    
  E-S grade    0.968                                     **\<0.001**                                     
  I-II         89            46                     43                               158   117     41    
  III-IV       75            39                     36                               73    37      36    
  TNM stage    **0.023**                                 **\<0.001**                                     
  I-II         86            60                     26                               132   113     19    
  III-IV~A~    71            37                     34                               91    59      32    
  AFP level    **\<0.001**                               **0.035**                                       
  \>20ng/ml    102           9                      93                               136   24      112   
  ≤20ng/ml     53            17                     36                               80    24      56    

\*Partial data were not available, and statistical analyses were performed using available data. GRK3, G-protein-coupled receptor kinase 3; HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; VI, Vascular invasion; E-S, Edmondson-Steiner; TNM, tumor-node-metastasis; AFP, α-fetoprotein.

###### 

Prognostic analysis for tumor-specific survival in training set of HCC

  Variables                       Univariate               Multivariate                            
  ----------------- ------------- ------------ ----------- -------------- -- ------- ------------- --
  Age               **0.007**                              0.204                                   
  ≥52 years         88            31.4±1.7     27.7-34.4                     0.691   0.390-1.223   
  \<52 years        76            24.0±1.8     20.5-27.6                     1                     
  Sex               0.860                                  0.574                                   
  Male              137           31.0±3.4     24.4-37.6                     0.779   0.327-1.858   
  Female            27            33.9±11.0    12.4-55.5                     1                     
  HBsAg             0.078                                  0.958                                   
  Positive          141           27.1±1.4     24.3-29.8                     1.037   0.272-3.949   
  Negative          20            34.6±3.2     28.4-40.9                     1                     
  Cirrhosis         0.177                                  0.388                                   
  Present           145           27.4±1.4     24.6-30.1                     2.011   0.412-9.831   
  Absent            17            32.8±3.4     26.1-39.5                     1                     
  Tumor size        **\<0.001**                            0.262                                   
  ≥5 cm             97            24.1±1.6     20.9-27.3                     1.412   0.773-2.581   
  \<5cm             67            33.2±1.8     20.8-36.7                     1                     
  VI                **0.011**                              0.764                                   
  Present           76            24.3±1.9     20.5-28.0                     1.089   0.624-1.903   
  Absent            80            31.2±1.7     27.8-34.6                     1                     
  E-S grade         **0.002**                              **0.015**                               
  I-II              89            31.5±1.6     28.4-34.6                     1                     
  III-IV            75            23.0±1.9     19.3-26.8                     2.046   1.149-3.642   
  TNM stage         **\<0.001**                            **0.038**                               
  I-II              86            34.5±1.5     31.5-37.4                     1                     
  III-IV~A~         71            21.5±1.9     17.8-25.3                     1.961   1.036-3.712   
  AFP level         0.096                                  0.333                                   
  \>20ng/ml         102           26.0±4.7     16.7-35.3                     1.331   0.746-2.375   
  ≤20ng/ml          53            33.5±5.1     23.6-43.4                     1                     
  GRK3 expression   **0.041**                              **0.006**                               
  High              100           35.5±3.0     29.6-41.4                     0.482   0.285-0.814   
  Low               64            24.0±3.5     17.1-30.9                     1                     

\*Partial data were not available, and statistical analyses were performed using available data. HCC, hepatocellular carcinoma; SE, standard error; CI, confidence interval; HR, hazard ratio; HBsAg, hepatitis B surface antigen; VI, Vascular invasion; E-S, Edmondson-Steiner; TNM, tumor-node-metastasis; AFP, α-fetoprotein; GRK3, G-protein-coupled receptor kinase 3.

###### 

Prognostic analysis for tumor-specific survival in validation set of HCC

  Variables                       Univariate                Multivariate                            
  ----------------- ------------- ------------ ------------ -------------- -- ------- ------------- --
  Age               0.691                                   0.353                                   
  ≥52 years         116           31.0±4.4     22.3-39.7                      1.202   0.815-1.774   
  \<52 years        115           33.0±8.0     17.2-48.8                      1                     
  Sex               0.679                                   0.850                                   
  Male              197           32.0±5.0     22.2-41.8                      1.058   0.590-1.896   
  Female            34            29.0±8.7     11.9-46.1                      1                     
  HBsAg             0.351                                   0.334                                   
  Positive          174           30.0±4.1     22.0-38.0                      1.351   0.734-2.485   
  Negative          44            69.0±24.0    21.9-116.1                     1                     
  Cirrhosis         0.193                                   0.958                                   
  Present           191           29.0±4.1     21.0-37.0                      0.982   0.502-1.923   
  Absent            38            49.0±18.2    13.2-84.8                      1                     
  Tumor size        **0.021**                               0.526                                   
  ≥5 cm             138           28.0±3.8     20.5-35.5                      1.154   0.741-1.797   
  \<5cm             74            66.0±14.2    38.1-93.9                      1                     
  VI                **\<0.001**                             **0.001**                               
  Present           116           20.0±4.9     10.5-29.5                      2.038   1.315-3.160   
  Absent            92            47.0±11.0    25.5-68.5                      1                     
  E-S grade         **0.037**                               0.533                                   
  I-II              158           43.0±6.3     30.7-55.3                      1                     
  III-IV            73            25.0±5.9     13.4-36.6                      1.144   0.749-1.749   
  TNM stage         **\<0.001**                             **0.005**                               
  I-II              132           57.0±16.4    24.8-89.2                      1                     
  III-IV~A~         91            17.0±4.7     7.8-26.2                       1.836   1.202-2.806   
  AFP level         0.078                                   0.107                                   
  \>20ng/ml         136           29.0±3.5     22.1-35.9                      1.396   0.930-2.094   
  ≤20ng/ml          80            47.0±11.2    25.0-69.0                      1                     
  GRK3 expression   **0.002**                               **0.012**                               
  High              179           42.0±6.3     29.7-54.3                      0.545   0.340-0.873   
  Low               52            16.0±6.1     4.1-27.9                       1                     

\*Partial data were not available, and statistical analyses were performed using available data. HCC, hepatocellular carcinoma; SE, standard error; CI, confidence interval; HR, hazard ratio; HBsAg, hepatitis B surface antigen; VI, Vascular invasion; E-S, Edmondson-Steiner; TNM, tumor-node-metastasis; AFP, α-fetoprotein; GRK3, G-protein-coupled receptor kinase 3.

###### 

Significant prognostic values of GRK3 expression and other variables in all patients and univariate log-rank test-identified subgroups of HCC (estimated by multivariate Cox regression test)

  Sets                  GRK3 expression   Other independent prognostic factors               
  --------------------- ----------------- -------------------------------------- ----------- -------------------------------------
  All patients          0.610             0.436-0.853                            **0.004**   E-S grade, VI, TNM stage
  Tumor size ≥5 cm      0.547             0.370-0.809                            **0.003**   E-S grade, VI, TNM stage, AFP level
  With VI               0.612             0.400-0.937                            **0.024**   TNM stage
  E-S grade I-II        0.663             0.419-1.050                            0.080       VI, TNM stage
  E-S grade III-IV      0.538             0.316-0.915                            **0.022**   None
  TNM stage III-IV~A~   0.541             0.344-0.850                            **0.008**   AFP level
  AFP level ≤20ng/ml    0.632             0.346-1.157                            0.137       E-S grade
  AFP level \>20ng/ml   0.552             0.365-0.835                            **0.005**   VI, TNM stage

\*Partial data were not available, and statistical analyses were performed using available data. GRK3, G-protein-coupled receptor kinase 3; HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; E-S, Edmondson-Steiner; VI, Vascular invasion; TNM, tumor-node-metastasis; AFP, α-fetoprotein.
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